Nephro-Urology Monthly

Published by: Kowsar

Antiproliferative and Antioxidant Effects of Withania coagulans Extract on Benign Prostatic Hyperplasia in Rats

Maryam Sarbishegi 1 , * , Mohaddeseh Khani 1 , Saeedeh Salimi 2 , Mohharam Valizadeh 3 and Fereydoon Sargolzaei Aval 1
Authors Information
1 Department of Anatomy, School of Medicine, Zahedan University of Medical Sciences, Zahedan, IR Iran
2 Cellular and Molecular Research Center, Zahedan University of Medical Sciences, Zahedan, IR Iran
3 Department of Medicinal and Aromatic Plant, High Complex Education of Saravan, Saravan, IR Iran
Article information
  • Nephro-Urology Monthly: January 01, 2016, 8 (1); e33180
  • Published Online: January 9, 2016
  • Article Type: Research Article
  • Received: September 15, 2015
  • Accepted: November 7, 2015
  • DOI: 10.5812/numonthly.33180

To Cite: Sarbishegi M, Khani M, Salimi S, Valizadeh M, Sargolzaei Aval F. Antiproliferative and Antioxidant Effects of Withania coagulans Extract on Benign Prostatic Hyperplasia in Rats, Nephro-Urol Mon. 2016 ; 8(1):e33180. doi: 10.5812/numonthly.33180.

Copyright © 2016, Nephrology and Urology Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. Shin IS, Lee MY, Ha HK, Seo CS, Shin HK. Inhibitory effect of Yukmijihwang-tang, a traditional herbal formula against testosterone-induced benign prostatic hyperplasia in rats. BMC Complement Altern Med. 2012; 12: 48[DOI][PubMed]
  • 2. Roehrborn CG. Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med Clin North Am. 2011; 95(1): 87-100[DOI][PubMed]
  • 3. Barkin J. Benign prostatic hyperplasia and lower urinary tract symptoms: evidence and approaches for best case management. Can J Urol. 2011; 18 Suppl: 14-9[PubMed]
  • 4. McVary KT. A review of combination therapy in patients with benign prostatic hyperplasia. Clin Ther. 2007; 29(3): 387-98[PubMed]
  • 5. Roehrborn CG, Rosen RC. Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily. Clin Interv Aging. 2008; 3(3): 511-24[PubMed]
  • 6. Gravas S, Oelke M. Current status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH. World J Urol. 2010; 28(1): 9-15[DOI][PubMed]
  • 7. Bullock TL, Andriole Jr GL. Emerging drug therapies for benign prostatic hyperplasia. Expert Opin Emerg Drugs. 2006; 11(1): 111-23[DOI][PubMed]
  • 8. Gerber GS. Phytotherapy for benign prostatic hyperplasia. Curr Urol Rep. 2002; 3(4): 285-91[PubMed]
  • 9. Beigomi M, Mohammadifar MA, Hashemi M, rohani MG, Senthil K, Valizadeh M. Biochemical and rheological characterization of a protease from fruits of Withania coagulans with a milk-clotting activity. Food Sci Biotechnol. 2014; 23(6): 1805-13[DOI]
  • 10. Gupta P. Withania coagulans Dunal-An Overview. Int J Pharmaceut. 2012; 12(2): 68-71
  • 11. Khodaei M, Jafari M, Noori M. Remedial Use of Withanolides from Withania Coagolans (Stocks) Dunal. Adv Life Sci. 2012; 2(1): 6-19[DOI]
  • 12. Ye L, Kynaston H, Jiang WG. Bone morphogenetic protein-9 induces apoptosis in prostate cancer cells, the role of prostate apoptosis response-4. Mol Cancer Res. 2008; 6(10): 1594-606[DOI][PubMed]
  • 13. Srinivasan S, Ranga RS, Burikhanov R, Han SS, Chendil D. Par-4-dependent apoptosis by the dietary compound withaferin A in prostate cancer cells. Cancer Res. 2007; 67(1): 246-53[DOI][PubMed]
  • 14. Nahata A, Dixit VK. Ameliorative effects of stinging nettle (Urtica dioica) on testosterone-induced prostatic hyperplasia in rats. Andrologia. 2012; 44 Suppl 1: 396-409[DOI][PubMed]
  • 15. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72(1-2): 248-54[DOI]
  • 16. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979; 95(2): 351-8[DOI]
  • 17. Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal Biochem. 1996; 239(1): 70-6[DOI][PubMed]
  • 18. Lai MD, Lee LR, Cheng KS, Wing LY. Expression of proliferating cell nuclear antigen in luminal epithelium during the growth and regression of rat uterus. J Endocrinol. 2000; 166(1): 87-93[PubMed]
  • 19. Atawia RT, Tadros MG, Khalifa AE, Mosli HA, Abdel-Naim AB. Role of the phytoestrogenic, pro-apoptotic and anti-oxidative properties of silymarin in inhibiting experimental benign prostatic hyperplasia in rats. Toxicol Lett. 2013; 219(2): 160-9[DOI][PubMed]
  • 20. Bostanci Y, Kazzazi A, Momtahen S, Laze J, Djavan B. Correlation between benign prostatic hyperplasia and inflammation. Curr Opin Urol. 2013; 23(1): 5-10[DOI][PubMed]
  • 21. Kullisaar T, Turk S, Punab M, Mandar R. Oxidative stress--cause or consequence of male genital tract disorders? Prostate. 2012; 72(9): 977-83[DOI][PubMed]
  • 22. Merendino RA, Salvo F, Saija A, Di Pasquale G, Tomaino A, Minciullo PL, et al. Malondialdehyde in benign prostate hypertrophy: a useful marker? Mediators Inflamm. 2003; 12(2): 127-8[DOI][PubMed]
  • 23. Ahmad M, Suhail N, Mansoor T, Banu N, Ahmad S. Evaluation of oxidative stress and DNA damage in benign prostatic hyperplasia patients and comparison with controls. Indian J Clin Biochem. 2012; 27(4): 385-8[DOI][PubMed]
  • 24. Pace G, Di Massimo C, De Amicis D, Corbacelli C, Di Renzo L, Vicentini C, et al. Oxidative stress in benign prostatic hyperplasia and prostate cancer. Urol Int. 2010; 85(3): 328-33[DOI][PubMed]
  • 25. Salwaan C, Singh A, Mittal A, Singh P. Investigation of the Pharmacognostical, Phytochemical and Antioxidant Studies of Plant Withania Coagulans Dunal. J Pharmacog Phytochem. 2012; 1: 36-44
  • 26. Hemalatha S, Wahi AK, Singh PN, Chansouria JP. Hypolipidemic activity of aqueous extract of Withania coagulans Dunal in albino rats. Phytother Res. 2006; 20(7): 614-7[DOI][PubMed]
  • 27. Rajasankar S, Manivasagam T, Surendran S. Ashwagandha leaf extract: a potential agent in treating oxidative damage and physiological abnormalities seen in a mouse model of Parkinson's disease. Neurosci Lett. 2009; 454(1): 11-5[DOI][PubMed]
  • 28. Sciarra A, Mariotti G, Salciccia S, Autran Gomez A, Monti S, Toscano V, et al. Prostate growth and inflammation. J Steroid Biochem Mol Biol. 2008; 108(3-5): 254-60[DOI][PubMed]
  • 29. Veeresh Babu SV, Veeresh B, Patil AA, Warke YB. Lauric acid and myristic acid prevent testosterone induced prostatic hyperplasia in rats. Eur J Pharmacol. 2010; 626(2-3): 262-5[DOI][PubMed]
  • 30. Oh JH, Lee TJ, Kim SH, Choi YH, Lee SH, Lee JM, et al. Induction of apoptosis by withaferin A in human leukemia U937 cells through down-regulation of Akt phosphorylation. Apoptosis. 2008; 13(12): 1494-504[DOI][PubMed]
  • 31. Aydin A, Arsova-Sarafinovska Z, Sayal A, Eken A, Erdem O, Erten K, et al. Oxidative stress and antioxidant status in non-metastatic prostate cancer and benign prostatic hyperplasia. Clin Biochem. 2006; 39(2): 176-9[DOI][PubMed]
  • 32. Kyprianou N, Tu H, Jacobs SC. Apoptotic versus proliferative activities in human benign prostatic hyperplasia. Hum Pathol. 1996; 27(7): 668-75[PubMed]
  • 33. Stan SD, Hahm ER, Warin R, Singh SV. Withaferin A causes FOXO3a- and Bim-dependent apoptosis and inhibits growth of human breast cancer cells in vivo. Cancer Res. 2008; 68(18): 7661-9[DOI][PubMed]
  • 34. Ichikawa H, Takada Y, Shishodia S, Jayaprakasam B, Nair MG, Aggarwal BB. Withanolides potentiate apoptosis, inhibit invasion, and abolish osteoclastogenesis through suppression of nuclear factor-kappaB (NF-kappaB) activation and NF-kappaB-regulated gene expression. Mol Cancer Ther. 2006; 5(6): 1434-45[DOI][PubMed]
  • 35. Choudhary MI, Yousuf S. Withanolides: Chemistry and Antitumor Activity. 2013; : 3465-95
  • 36. Huo JX, Metz SA, Li GD. p53-independent induction of p21(waf1/cip1) contributes to the activation of caspases in GTP-depletion-induced apoptosis of insulin-secreting cells. Cell Death Differ. 2004; 11(1): 99-109[DOI][PubMed]
  • 37. Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature. 1994; 369(6481): 574-8[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments